SITE006-0060

SITE006 (GBR) › SITE006-0060

SITE006-0060

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2025-11-15

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-14 (study day 210); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 205); relationship: NOT RELATED

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 177); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 98); relationship: not assessed

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-26 (study day 69); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.